Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study

Giuseppe Lopalco, Giacomo Emmi, Stefano Gentileschi, Silvana Guerriero, Antonio Vitale, Elena Silvestri, Matteo Becatti, Iacopo Cavallo, Claudia Fabiani, Bruno Frediani, Florenzo Iannone, Luca Cantarini

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: The purpose of the present study was to describe our experience with the recombinant Fab' antibody fragment against TNF-α Certolizumab Pegol (CZP) in patients with Behçet's disease (BD) refractory to standardized therapies and previous biologic agents.

METHODS: Retrieved data including demographic characteristics, clinical manifestations, and previous treatments were collected in three different specialized Rheumatologic Units in Italy. In order to evaluate disease activity, the BD current activity form (BDCAF) has been used before starting CZP therapy and at each visit during treatment.

RESULTS: Thirteen BD patients (mean age 42.6 ± 8.8 years) with a disease duration of 8.80 ± 6.9 years, underwent CZP treatment for 6.92 ± 3.52 months. Six patients (46.15%) experienced a worsening of symptoms after 4.16 ± 1.21 months, whereas a satisfactory response was achieved in seven patients (53.84%) who were still on CZP therapy at the last follow-up visit (after 9.28 ± 3.03 months of treatment). The mean decrease of BDCAF between the first and last visit was 0.308 ± 1.84 without reaching significant difference (mean 8.3 ± 1.3 and 8 ± 2.08, respectively; p= .51). During the whole study period, CZP was well tolerated in all patients except one who developed a generalized cutaneous reaction after the third administration.

CONCLUSIONS: These results suggest that despite an improvement of clinical manifestations has been observed in more than half of the patients, it is not possible to draw firm conclusions about the effectiveness of CZP in BD and further studies with larger cohorts of patients are warranted. Whether the increase of CZP dosage may ensure a better clinical response remains an unsolved issue that needs to be considered.

Original languageEnglish
Pages (from-to)1031-1035
Number of pages5
JournalModern Rheumatology
Volume27
Issue number6
DOIs
Publication statusPublished - Nov 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study'. Together they form a unique fingerprint.

Cite this